Article

Genetically informed drug target prioritisation and repurposing for major depressive disorder

2025-07-16

Abstract excerpt

Major depressive disorder (MDD) treatments have limited efficacy and target few mechanisms, highlighting the need for innovative drug discovery. Drugs targeting genetically supported proteins are 2.6 times more likely to succeed in drug development. Here, we use genetic methods to identify and prioritise MDD drug targets, leveraging genome-wide association study (GWAS) summary statistics from >525,000 MDD cases. W...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 554fba21-1c6b-514b-9bde-65990174b508
DOI: 10.1101/2025.07.15.25331558

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Genetically informed drug target prioritisation and repurposing for major depressive disorderDOI 10.1101/2025.07.15.25331558Read

Using genetic drug-target networks to develop new drug hypotheses for major depressive disorderSemantic proximity Read

Leveraging the genetics of psychiatric disorders to prioritize potential drug targets and compounds.Semantic proximity Read

Leveraging the Genetics of Psychiatric Disorders to Prioritize Potential Drug Targets and CompoundsSemantic proximity Read

Mendelian Randomization Using the Druggable Genome Reveals Genetically Supported Drug Targets for Psychiatric Disorders.Semantic proximity Read

Convergent proteogenomic evidence prioritises five causal proteins and new drug targets for major psychiatric disordersSemantic proximity Read

Identifying drug targets for neurological and psychiatric disease via genetics and the brain transcriptome.Semantic proximity Read

Genetic Landscape of Major Depressive Disorder: Assessment of Potential Diagnostic and Antidepressant Response MarkersSemantic proximity Read

Pathway-based polygenic risk implicates GO: 17144 drug metabolism in recurrent depressive disorderSemantic proximity Read

Deciphering the genetic underpinnings of neuroticism: A Mendelian randomization study of druggable gene targets.Semantic proximity Read

Prioritization of novel druggable targets for epilepsy via Mendelian randomization and colocalization.Semantic proximity Read

Identification of 64 new risk loci for major depression, refinement of the genetic architecture and risk prediction of recurrence and comorbiditiesSemantic proximity Read

Translating GWAS Findings Into Therapies For Depression And Anxiety Disorders: Drug Repositioning Using Gene-Set Analyses Reveals Enrichment Of Psychiatric Drug ClassesSemantic proximity Read